Please login to the form below

Not currently logged in
Email:
Password:

Celltrion

This page shows the latest Celltrion news and features for those working in and with pharma, biotech and healthcare.

Teva names new CFO and bulks up its opioid liability fund

Teva names new CFO and bulks up its opioid liability fund

One bright spot for the company this week was the US launch of Celltrion-partnered Truxima – the first biosimilar of Roche’s big-selling Rituxan (rituximab) to reach the US market – ... rheumatoid arthritis, Teva and Celltrion’s drug is expected

Latest news

More from news
Approximately 13 fully matching, plus 39 partially matching documents found.

Latest Intelligence

  • 2016: The year when deal-makers took stock? 2016: The year when deal-makers took stock?

    This has provided an opportunity for companies specialising in development of biosimilars to win deals from big companies, such as the $160m agreement between Teva and Celltrion in the US and

  • Deal Watch October 2016 Deal Watch October 2016

    For example in Europe both Pfizer (Hospira) in 2009 and Mundipharma in 2014 have rights to Celltrion's infliximab. ... 175. Celltrion (SK). Teva (IS). Co-commercialisation. Biosimilar rituximab and trastuzumab in phase III in North America.

  • Biosimilars - the same, but different? Biosimilars - the same, but different?

    This first infliximab biosimilar was developed and manufactured by Celltrion and is marketed by various partners, notably Hospira under the brand name Inflectra and Mundipharma as Remsima.

  • Pharma deals in February 2015 Pharma deals in February 2015

    Assets that Hospira acquired with Celltrion are essentially replicas of existing Pfizer programmes eg Herceptin and Rituxan and these will probably be divested.

  • Current development and marketing of biosimilar monoclonal antibodies in Latin America Current development and marketing of biosimilar monoclonal antibodies in Latin America

    Celltrion. South Korea. CT-P10. Clinical. FL: Phase III started in Dec 2011. ... 7). OliMed. Trastuzumab. Celltrion. South Korea. CT-P06. Clinical. BC: Ph III completed in Dec 2011.

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Data desires
What are you looking to achieve with data and how are you preparing yourself to react to the results?...
The balancing act that’s keeping pharma and biotech market access on its toes
Pricing drugs and gaining reimbursement can be a real challenge for drug developers. Price it too high, and no one buys it. Price it too low, and it’s hard to...
Pills
Tackling antimicrobial resistance on multiple fronts
An urgent change of direction is needed in how we respond to AMR...

Infographics